


SARS-CoV-2 Rapid Antigen Test Nasal

Convenient sampling, quick results



Introducing the SARS-CoV-2 Rapid Antigen Test Nasal



Less invasive point-of-care testing with increased protection for healthcare professionals

Key benefit



Shelf life: 24 months after manufacturing date



1× positive and negative QC included in the kit





Storage temperature

Cross-reactivity

SARS-CoV-2

Rapid Ag

No instruments needed


SARS-CoV-2 Rapid Ag

SARS-CoV-2

Rapid Ag

SARS-CoV-2

Rapid Ag



54 human-pathogenic specimens tested negative for cross-reactivity.* 15 potential substances tested negative for interference. Test description


The SARS-CoV-2 Rapid Antigen Test Nasal is a rapid chromatographic immunoassay for the qualitative detection of SARS-CoV-2 nucleocapsid antigen present in human nasal samples.

This assay is intended to detect antigen from SARS-CoV-2 in individuals suspected of COVID-19 or with known or suspected exposure to SARS-CoV-2. The test is intended for professional use in laboratory and point-of-care environments, or self-collection under the supervision of a healthcare worker.


3

Performing a test in 4 easy steps









Nasal swab collection

Insert a sterile swab 2 cm into the patient's nostril with the most secretion. Rotate the swab 4 times for about 15 seconds against the nasal wall. Remove it from the nostril. Repeat procedure with the same swab in the other nostril.

Prepare the sample


- A Insert the swab into an extraction buffer tube, squeeze the tube and stir the swab >10×.
- **B** Remove the swab while squeezing the sides of the tube.
- **C** Press the nozzle cap tightly onto the tube.

of the patient's recent exposures,

signs and symptoms consistent

with COVID-19.

history and the presence of clinical



Add 4 drops of extracted sample to the specimen well of the test device.


or ELISA if necessary for patient

management.

Read the test result in 15 – 30 min

Do not read test result after 30 minutes.

Quick and easy to read



Performance compared to PCR tests

Direct detection of the virus – through nucleic acid and antigen testing – is essential to contain the virus and make further treatment as well as quarantine decisions.


PCR tests are intended for the qualitative detection of SARS-CoV-2 in nasopharyngeal and oropharyngeal swab samples from patients.²

Rapid antigen tests detect the presence of a specific viral protein. A positive result requires a higher viral load than a PCR test for reliable antigen detection and a high test performance.

Centers for Disease Control and Prevention (CDC) recommend rapid antigen testing as diagnostic testing of individuals suspected of COVID-19 or with known or suspected exposure to SARS-CoV-2. (e.g. via contract tracing tools). The World Health Organisation (WHO) recommends screening of asymptomatics environments (institutions, carehomes, schools etc.) where PCR is not immediately available.^{3, 4, 5}


Both institutions recommend antigen testing within 5–7 days post symptom onset as during that time viral load is highest.^{3, 4, 5}

PCR tests are considered the gold standard due to the highest analytical sensitivity on the market. However, SARS-CoV-2 rapid antigen tests support to trace infectious individuals in decentralized locations, especially when lab testing isn't available and time is of the essence.



Clinical Sensitivity of a Rapid Test compared to PCR⁶

Structure of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)⁷



Summary of sample characteristics¹

	Overall	HCP collection	Self-collection
Ν	696	311	385
Asymptomatic, n/N (%)	20/696 (2.9%)	7/311 (2.3%)	13/385 (3.4%)
Symptomatic, n/N (%)	676/696 (97.1%)	304/311 (97.7%)	372 / 385 (96.6%)
DPSO, median (range)	3 (0 – 27)	3 (0 – 15)	4 (0-27)
PCR positive, n/N (%)	150/696 (21.6%)	77/311 (24.8%)	73/385 (19.0%)
PCR positive symptomatic, n/N (%)	147/150 (98.0%)	75/77 (97.4%)	72/73 (98.6%)
PCR positive asymptomatic, n/N (%)	3/150 (2.0%)	2/77 (2.6%)	1/73 (1.4%)
PCR negative, n/N	546/696 (78.4%)	234/311 (75.2%)	312/385 (81.0%)
PCR sample type	Combined OP/NP	Combined OP/NP	Combined OP/NP

Performance overview¹

For professionally collected samples, the test was found to have a sensitivity of 89.6 % (Ct \leq 30) and a specificity of 99.1 %.***

Sensitivity	Professional collection	Self-collection
Ct ≤ 24, (95 % Cl), N	97.7 % (88.0 % – 99.9 %), 44	97.9% (88.7% – 99.9%), 47
Ct ≤ 27, (95 % Cl), N	93.1 % (83.3 % – 98.1 %), 58	94.7% (85.4% – 98.9%), 57
Ct ≤ 30, (95 % Cl), N	89.6% (79.7%–95.7%), 67	89.1 % (78.8 % – 95.5 %), 64
Ct ≤ 33, (95 % Cl), N	87.1 % (77.0 % – 93.9 %), 70	84.5% (74.0% – 92.0%), 71
All Ct values, (95% Cl), N	83.1 % (72.9%–90.7%), 77	82.2% (71.5%–90.2%), 73

Limit of detection SARS-CoV-2 (2019-nCOV) NCCP 43326/2020

Concentration 9.25 × 10^{1.2} TCID₅₀/mL

Specificity


All Ct values, (95% Cl), N

99.1 % (96.9 % – 99.9 %), 234

99.0 % (97.2 % – 99.8 %), 312

Your kit for convenient sampling with quick results

- \rightarrow Results in 15 30 minutes
- → Less invasive and more convenient testing
- → Increased protection for healthcare workers



Ordering information

				Roche				
Product	REF #	GTIN	Cat #	Material #	PZN (DE only)			
Languages 1 – 8: Spanish, Portuguese, German, French, Italian, Dutch, Swedish, Turkish								
SARS-CoV-2 Rapid Antigen Test Nasal	9901-NCOV-03G	08809319398233	99COV33D-ML01	09365397023	1173555			
Languages 9 – 16: English (CE), Hungarian, Czech, Polish, Russian, Norwegian, Danish, Finnish								
SARS-CoV-2 Rapid Antigen Test Nasal	9901-NCOV-03G	08809319398240	99COV33D-ML02	09365397043	/			

References

- 1 SARS-CoV-2 Rapid Antigen Test Nasal Method Sheet (V2, April 2021).
- 2 Wölfel, R. et al. (2020). Virological assessment of hospitalized patients with COVID-2019 581 (7809), 465-469.
- 3 CDC. https://www.cdc.gov/coronavirus/2019-nCoV/hcp/clinical-criteria.html.
- 4 Criteria to Guide Evaluation and Laboratory Testing for COVID-19.
- Available at: https://www.cdc.gov/coronavirus/2019-nCoV/hcp/clinical-criteria.html. Accessed Sept 11, 2020.
 COVID-19 (Rapid) Antigen Testing Recommendations WHO update September 11th 2020.
- Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/ technical-guidance-publications?publicationtypes=f85a3610-b102-4287-a6df-f3bc0b2e9f7c.
- 6 Huang, C et al. (2020). Lancet 395, 497-506.
- 7 Masters PS (2006). Advances in Virus Research. Academic Press. 6

Published by

Roche Diagnostics NZ Ltd ANZ Raranga Building, Level 1, Sylvia Park 286 Mount Wellington Highway Mount Wellington, Auckland 1060 New Zealand

© 2021

All trademarks mentioned enjoy legal protection.

diagnostics.roche.com